Essential Pharma Group has $966M on record. The latest round is a $966M Growth (December 2024). Size your own round against the evidence it must buy, not against the stage letter.
Key takeaways
- Round size should be derived from the evidence the next investor needs, not from the stage label.
- Named participants on a record tell you which funds write at this size and stage.
- Plan the raise timeline backwards from your cash-out date, with a third added for slippage.
Not every round gets a letter. Growth capital is negotiated against different evidence: retention, unit economics and a credible path to funding operations without the next round.
The record here belongs to Emma Johnson, founder of Essential Pharma Group (Egham, UK).
| | | |---|---| | Founder | Emma Johnson | | Company | Essential Pharma Group (Egham, UK) | | Total raised | $966M | | Latest round | Growth — $966M | | Round date | December 2024 | | Named participants on record | Gyrus Capital, AlpInvest, Sixth Street |
Lifetime capital equals this round. Anything earlier was small, undisclosed or non-dilutive.
The round size sets the next evidence bar. Investors size the following round against what this one was expected to buy. Write that expectation down before you sign.
Named participants signal the buyer pool. Gyrus Capital, AlpInvest, Sixth Street are on record here. Funds with that profile are the realistic audience for a comparable raise.
Timing is data. The round closed in December 2024. Fundraises take longer than founders plan; count backwards from the date you need cash, not from the date you want a term sheet.
1. Write the two or three pieces of evidence your next round must show. 2. Cost out the months and headcount required to produce that evidence, then add a third for slippage. 3. Build the investor list from funds that have written cheques of this size at this stage, not from brand preference. 4. Ask each lead what they expect to see at the next round, and hold them to it in writing.
The letter on the round matters far less than whether the money buys the evidence the next buyer needs.
Frequently asked questions
- How much has Emma Johnson raised for Essential Pharma Group?
- Essential Pharma Group has $966M in disclosed funding on record, most recently a $966M Growth in December 2024.
- Who invested in Essential Pharma Group?
- Named participants on record include Gyrus Capital, AlpInvest, Sixth Street. Records list participants, not allocations or terms.
- Where do these figures come from?
- Structured founder funding records: total raised, round stage, round amount, round date and named participants. They exclude valuation, terms and board composition.
